肝细胞癌廓清在肝胆与细胞外对比剂MRI中的个体内比较
该研究前瞻性纳入114例慢性肝病患者,术前均行肝胆对比剂MRI和细胞外对比剂MRI,个体内比较肝细胞癌廓清表现。结果显示两种对比剂的门静脉期/延迟期廓清频率及LR-5敏感度总体相当,但<20 mm病灶中肝胆对比剂MRI的LR-5敏感度更高(70.8% vs 50.0%,p=0.034),加入假性廓清后敏感度相似。
要点
- 肝胆对比剂MRI门静脉期廓清与细胞外对比剂MRI延迟期廓清频率相当(77.2% vs 68.4%,p=0.134)。
- <20 mm肝细胞癌中肝胆对比剂MRI的LR-5敏感度高于细胞外对比剂MRI(70.8% vs 50.0%,p=0.034)。
- 细胞外对比剂MRI加入假性廓清后<20 mm病灶敏感度与肝胆对比剂MRI相似(70.8% vs 72.9%,p>0.999)。
关键影像表现/征象
- 采用5分法(-2至+2)评估病灶与肝实质视觉信号强度比(SIR),廓清定义为视觉SIR为负且较动脉期时间性降低。
- 假性廓清定义为视觉SIR为0且伴强化包膜。
- 肝胆对比剂MRI门静脉期廓清频率77.2%(88/114),细胞外对比剂MRI延迟期廓清频率68.4%(78/114),p=0.134。
- 允许假性廓清时,肝胆对比剂MRI廓清频率79.8%(91/114),细胞外对比剂MRI为81.6%(93/114),p=0.845。
诊断标准与关键数值
- LR-5(使用门静脉期或延迟期廓清)诊断肝细胞癌敏感度:肝胆对比剂MRI 78.1%(89/114) vs 细胞外对比剂MRI 73.7%(84/114),p=0.458。
- <20 mm肝细胞癌中LR-5敏感度:肝胆对比剂MRI 70.8%(34/48) vs 细胞外对比剂MRI 50.0%(24/48),p=0.034。
- <20 mm肝细胞癌中LR-5加入假性廓清后敏感度:肝胆对比剂MRI 72.9%(35/48) vs 细胞外对比剂MRI 70.8%(34/48),p>0.999。
临床应用与阅片要点
- 阅片时注意肝胆对比剂MRI采用门静脉期评估廓清,细胞外对比剂MRI采用延迟期评估廓清。
- 对<20 mm病灶,细胞外对比剂MRI可考虑结合假性廓清(SIR为0伴强化包膜)以提高诊断敏感度。
- 报告肝细胞癌廓清时需明确所使用对比剂类型及对应评估时相。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To intraindividually compare hepatocellular carcinoma (HCC) washout between MRIs using hepatobiliary agent (HBA) and extracellular agent (ECA).
MATERIALS AND METHODS: This study included 114 prospectively enrolled patients with chronic liver disease (mean age, 55 ± 9 years; 94 men) who underwent both HBA-MRI and ECA-MRI before surgical resection for HCC between November 2016 and May 2019. For 114 HCCs, the lesion-to-liver visual signal intensity ratio (SIR) using a 5-point scale (-2 to +2) was evaluated in each phase. Washout was defined as negative visual SIR with temporal reduction of visual SIR from the arterial phase. Illusional washout (IW) was defined as a visual SIR of 0 with an enhancing capsule. The frequency of washout and MRI sensitivity for HCC using LR-5 or its modifications were compared between HBA-MRI and ECA-MRI. Subgroup analysis was performed according to lesion size (< 20 mm or ≥ 20 mm).
RESULTS: The frequency of portal venous phase (PP) washout with HBA-MRI was comparable to that of delayed phase (DP) washout with ECA-MRI (77.2% [88/114] vs. 68.4% [78/114]; p = 0.134). The frequencies were also comparable when IW was allowed (79.8% [91/114] for HBA-MRI vs. 81.6% [93/114] for ECA-MRI; p = 0.845). The sensitivities for HCC of LR-5 (using PP or DP washout) were comparable between HBA-MRI and ECA-MRI (78.1% [89/114] vs. 73.7% [84/114]; p = 0.458). In HCCs < 20 mm, the sensitivity of LR-5 was higher on HBA-MRI than on ECA-MRI (70.8% [34/48] vs. 50.0% [24/48]; p = 0.034). The sensitivity was similar to each other if IW was added to LR-5 (72.9% [35/48] for HBA-MRI vs. 70.8% [34/48] for ECA-MRI; p > 0.999).
CONCLUSION: Extracellular phase washout for HCC diagnosis was comparable between MRIs with both contrast agents, except for tumors < 20 mm. Adding IW could improve the sensitivity for HCC on ECA-MRI in tumors < 20 mm.
引用
- Kim YY, Kim YK, Min JH, et al. Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents. Korean J Radiol. 2021. PMID: 33660458. doi:10.3348/kjr.2020.1143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。